Search Results

You are looking at 1 - 8 of 8 items for :

  • "mRNA vaccine" x
  • Refine by Access: All x
Clear All
Full access

Adam J. Widman, Bevin Cohen, Vivian Park, Tara McClure, Jedd Wolchok, and Mini Kamboj

validate the overall safety of immunization. 4 Still, with higher rates of immediate postvaccine adverse reactions with mRNA vaccines, 5 concerns have emerged about the risk for immune-related adverse events (irAEs) after COVID-19 immunization. In

Full access

approval but cautions that they are still awaiting data on bivalent booster effectiveness in immunocompromised people. • Moderna is the preferred mRNA vaccine for pediatric immunosuppressed patients aged 6 months to 17 years. • Preliminary data show

Full access

guide and incorporates the latest data plus recent approvals from the FDA and CDC regarding a third mRNA vaccine dose for immunocompromised people. The updated guidance is available for free at NCCN.org/covid-19 . The NCCN COVID-19 Vaccination

Full access

or mAbs) for people with cancer; this treatment should not be viewed as a substitution for vaccination. • Updated data on mixing mRNA vaccine types, which is now considered to have similar effectiveness compared to using the same vaccine type

Full access

Presenter: Maria Alma Rodriguez

ages of 19 and 64 years and repeated at ≥65 years. 6 Vaccination against the current leading cause of pneumonia, COVID-19, is recommended by NCCN and the CDC in patients with cancer and cancer survivors. 1 , 7 The available mRNA vaccines are

Full access

Rebecca M. Shulman, David S. Weinberg, Eric A. Ross, Karen Ruth, Glenn F. Rall, Anthony J. Olszanski, James Helstrom, Michael J. Hall, Julia Judd, David Y.T. Chen, Robert G. Uzzo, Timothy P. Dougherty, Riley Williams, Daniel M. Geynisman, Carolyn Y. Fang, Richard I. Fisher, Marshall Strother, Erica Huelsmann, Sunil Adige, Peter D. Whooley, Kevin Zarrabi, Brinda Gupta, Pritish Iyer, Melissa McShane, Hilario Yankey, Charles T. Lee, Nina Burbure, Lauren E. Laderman, Julie Giurintano, Samuel Reiss, and Eric M. Horwitz

dispensing COVID-19 vaccine to patients with cancer. The current study addresses only the short-term adverse events of COVID-19 vaccine in patients with cancer. Reassuringly, early reports suggest that the 2-dose protocol of mRNA vaccine induces immunity in

Full access

immunized, including third doses and/or any approved boosters; There is a strong preference for mRNA vaccines; Vaccination should be delayed for at least 3 months following hematopoietic cell transplantation or engineered cellular therapy (eg, CAR T

Full access

patients with a history of heparin-induced thrombocytopenia and/or thrombosis to consider mRNA vaccines instead of the AdV-type 26 vector vaccine. The committee also cautions against antibody testing outside of a study, and encourages more research on the